Horizon's Arthritis Drug Patent Under Scrutiny At PTAB
Mylan Pharmaceuticals and Horizon Pharma faced off Friday at the Patent Trial and Appeal Board, where the generic drugmaker fought to persuade the three-judge panel to invalidate a patent covering Horizon's...To view the full article, register now.
Already a subscriber? Click here to view full article